Careers  |  Sign In  |  Register  |   Twitter
Series Progress
Part 1
Part 2
Part 3
Part 4

Part 2

Efficacy of SGLT2 Cotransporter Inhibition in T2DM

Free CME

Downloadable Education Resources

Sponsorship Statement

This continuing medical education activity is sponsored byVindico Medical Education

Support Statement

This activity is supported by an educational grant from

Target Audience

The intended audience for the activities is endocrinologists, diabetologists, primary care physicians and other healthcare professionals involved in the treatment of patients with type 2 diabetes mellitus (T2DM).

Learning Objectives

At the conclusion of this video series participants should be able to:

  • Examine the role of the kidney in glucose homeostasis and the rationale for targeting the SGLT2 cotransporter for the treatment of type 2 diabetes.
  • Evaluate the safety and efficacy data for newly approved and investigational SGLT2 inhibitors for clinical use in patients with T2DM.
  • Select treatment regimens for type 2 diabetes that are safe and effective in patients who may be at increased risk for cardiovascular disease.

Overview

Recent advances with novel orally administered SGLT2 cotransporter inhibitors, a new class of anti-diabetic agent that inhibits glucose absorption from the kidney tubule independent of insulin, offers a unique opportunity to address current unmet therapeutic needs and improve outcomes for the patient with T2DM. The recent FDA approval of a once daily formulation offers an important new treatment option for higher-risk adult patients with T2DM. Several other SGLT2 inhibitors are in the late stages of development. Optimal use of this new class of agents will require that clinicians understand the link between the kidney and glucose homeostasis, and the rationale for SGLT2 as a therapeutic target. This activity will focus on the evidence that supports the safety and efficacy of this new class of agents, an understanding of its effects and adverse events so clinicians are able to confidently use these agents in practice.

Faculty

George Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
The University of Chicago Medicine
Chicago, IL

Vivian A. Fonseca, MD, FRCP
Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, LA

Anne L. Peters, MD, FACP, CDE
Director, USC Clinical Diabetes Programs
University of Southern California
Los Angeles, CA

Carol H. Wysham, MD
Clinical Assistant Professor of Medicine
University of Washington School of Medicine
Section Head, Endocrinology
Rockwood Clinic
Spokane, WA

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™, 0.25 credits per video. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release: December 26, 2013 to December 26, 2014.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of each of videos posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Planning Committee and Faculty:

George Bakris, MD
Vivian A. Fonseca, MD, FRCP
Anne L. Peters, MD, FACP, CDE
Carol H. Wysham, MD

External Reviewer:

Ronald Codario Jr., MD

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

  • Planning Committee and Faculty members report the following relationship(s):
    • George Bakris, MD
      • Consulting Fees: AbbVie, Daiichi-Sankyo, Janssen, Medtronic, Relypsa, Takeda
    • Vivian A. Fonseca, MD, FRCP
      • Research Support: Abbott, Eli Lilly, Endo Barrier, Novo Nordisk, Pan American Laboratories, Reata, Sanofi-Aventis
      • Consulting Fees: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Novo Nordisk, Pamlabs, Sanofi-Aventis, Takeda
    • Anne L. Peters, MD, FACP, CDE
      • Consulting Fees: Abbott Diabetes Care, Becton Dickinson, Bristol-Myers Squibb/AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Medtronic Minimed, Sanofi, Takeda
      • Speakers Bureau: Bristol-Myers Squibb/AstraZeneca, Novo Nordisk
    • Carol H. Wysham, MD
      • Speakers Bureau: Bristol-Myers Squibb/Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi-Aventis
      • Contracted Research: Bristol-Myers Squibb/Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Sanofi-Aventis
  • External Reviewer reports the following relationship(s):
    • Ronald Codario Jr., MD
      • No relevant financial relationships to disclose.
  • Vindico Medical Education staff report the following relationship(s):
    • No relevant financial relationships to disclose.
  • BetterCME staff report the following relationship(s):
    • The medical director, Maya Mehta, MD, MBA, and production staff of BetterCME have no relevant financial relationships to disclose.
  • Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Questions?

Contact us at cme@vindicomeded.com